# Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

> **NCT01454102** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 472 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Erlotinib
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT01454102
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-16
- **Primary completion:** 2016-07-20
- **Final completion:** 2021-07-23
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454102, "Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01454102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*